Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia

Shukaib Arslan; Jianying Zhang; Prajwal Dhakal; Jenna Moran; Nuthana Naidoo; Jennifer Lombardi; Vinod Pullarkat; Anthony S. Stein; Guido Marcucci; George Yaghmour; Vijaya R. Bhatt; Amir T. Fathi; Ibrahim Aldoss

doi:10.1002/ajh.26057

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia

Shukaib Arslan, Jianying Zhang, Prajwal Dhakal, Jenna Moran, Nuthana Naidoo, Jennifer Lombardi, Vinod Pullarkat, Anthony S. Stein, Guido Marcucci, George Yaghmour, Vijaya R. Bhatt, Amir T. Fathi, Ibrahim Aldoss

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	E59-E63
Journal	American Journal of Hematology
Volume	96
Issue number	3
DOIs	https://doi.org/10.1002/ajh.26057
State	Published - Mar 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26057

Cite this

Arslan, S., Zhang, J., Dhakal, P., Moran, J., Naidoo, N., Lombardi, J., Pullarkat, V., Stein, A. S., Marcucci, G., Yaghmour, G., Bhatt, V. R., Fathi, A. T., & Aldoss, I. (2021). Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. American Journal of Hematology, 96(3), E59-E63. https://doi.org/10.1002/ajh.26057

@article{70e3e102691446198ba6b0d016403654,

title = "Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia",

author = "Shukaib Arslan and Jianying Zhang and Prajwal Dhakal and Jenna Moran and Nuthana Naidoo and Jennifer Lombardi and Vinod Pullarkat and Stein, {Anthony S.} and Guido Marcucci and George Yaghmour and Bhatt, {Vijaya R.} and Fathi, {Amir T.} and Ibrahim Aldoss",

note = "Funding Information: A.S.S. serves on the speaker bureau for Stemline, Amgen and Celgene, and on advisory boards for Stemline and Amgen. G.M. is a member of the speakers' bureau for AbbVie and Novartis, and serves on advisory board with Janssen Pharm. V.P. has served on the advisory boards for AbbVie and Jazz Pharmaceuticals and is member of speakers' bureau for Jazz, Amgen, Novartis and AbbVie. G.Y. served on Advisory Boards for Novartis, Agios and Takeda, and speaker for Jazz Pharmaceutical, Takeda, Astellas, Alexion and BMS. V.R.B. served as consultant for Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Jazz Pharmaceuticals and Partnership for health analytic research, and research funding from Abbvie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program, Oncoceutics, and Novartis. A.T.F. served as consultant for Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol‐Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead, and research support from Celgene/BMS, Seattle Genetics, Takeda, and Agios. I.A. has served on advisory boards with AbbVie, Amgen, KiTE pharmaceuticals, Agios, consultant for Autolus and Amgen, speaker for Jazz Pharmaceuticals. The remaining authors have no relevant conflict of interest to declare. ",

year = "2021",

month = mar,

day = "1",

doi = "10.1002/ajh.26057",

language = "English (US)",

volume = "96",

pages = "E59--E63",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia

AU - Arslan, Shukaib

AU - Zhang, Jianying

AU - Dhakal, Prajwal

AU - Moran, Jenna

AU - Naidoo, Nuthana

AU - Lombardi, Jennifer

AU - Pullarkat, Vinod

AU - Stein, Anthony S.

AU - Marcucci, Guido

AU - Yaghmour, George

AU - Bhatt, Vijaya R.

AU - Fathi, Amir T.

AU - Aldoss, Ibrahim

N1 - Funding Information: A.S.S. serves on the speaker bureau for Stemline, Amgen and Celgene, and on advisory boards for Stemline and Amgen. G.M. is a member of the speakers' bureau for AbbVie and Novartis, and serves on advisory board with Janssen Pharm. V.P. has served on the advisory boards for AbbVie and Jazz Pharmaceuticals and is member of speakers' bureau for Jazz, Amgen, Novartis and AbbVie. G.Y. served on Advisory Boards for Novartis, Agios and Takeda, and speaker for Jazz Pharmaceutical, Takeda, Astellas, Alexion and BMS. V.R.B. served as consultant for Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Jazz Pharmaceuticals and Partnership for health analytic research, and research funding from Abbvie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program, Oncoceutics, and Novartis. A.T.F. served as consultant for Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol‐Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead, and research support from Celgene/BMS, Seattle Genetics, Takeda, and Agios. I.A. has served on advisory boards with AbbVie, Amgen, KiTE pharmaceuticals, Agios, consultant for Autolus and Amgen, speaker for Jazz Pharmaceuticals. The remaining authors have no relevant conflict of interest to declare.

PY - 2021/3/1

Y1 - 2021/3/1

UR - http://www.scopus.com/inward/record.url?scp=85097309604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097309604&partnerID=8YFLogxK

U2 - 10.1002/ajh.26057

DO - 10.1002/ajh.26057

M3 - Letter

C2 - 33227142

AN - SCOPUS:85097309604

SN - 0361-8609

VL - 96

SP - E59-E63

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 3

ER -

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this